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Examplesofacombinedapproach usingin vivoaswell asin vitromethodsforthe assessmentofprenatal
toxicity are presented. The topics discussed include the analysis ofthe possible embryotoxic potential of
valproic acid(VPA), female sexhormones, bis(tri-n-butyltin) oxide(TBTO), andacyclovirandthe problem
of supplementing in vitro systems with drug-metabolizing activity.
Introduction
Supplementation of the classical in vivo tests with
recently developed in vitro techniques has greatly ex-
tended the scientific possibilities in prenatal toxicology
(1-3). Inthis presentation we shall give some examples
ofsuch a combined approach as extensively used in our
institute in recent years. We strongly feel that onlythe
concerted use of in vivo methods, in vitro techniques,
pharmacokinetic studies, and additional specific mor-
phological (especially electron microscopic) and bio-
chemical investigations will allow us to successfully tac-
kle the important problems in revealing the principles
and special aspects of prenatal toxicity in the years to
come.
On the other hand, one should be aware of the pos-
sibility of producing "artifacts" in vitro; misinterpre-
tation ofthe data may occur easily and must be avoided
(4). One ofthe major difficulties still connected with in
vitro methods istodistinguishgeneralcytotoxiceffects,
which may be produced with any substance at a high
enough concentration, from specific interferences with
differentiation processes.
None of the culture methods available today are,
alone, adequate fortacklingthe varietyofproblems and
all ofthem have considerable limitations as well as ad-
vantages; the most suitable method has to be selected
for solving a special problem.
Here wepresentresultsofstudiessupplemented with
different culture techniques on some aspects of abnor-
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malprenataldevelopmentinducedbyvalproicacidstud-
ied with the "whole-embryo" culture technique which
we have modified for use on a larger scale; the question
of a possible induction of abnormal heart development
by some female sex hormones ("whole-embryo" culture
technique); the problem ofassessingapossible embryo-
toxic potential ofbis(tri-n-butyltin) oxide (TBTO) from
in vivo and in vitro data (limb bud assay); the problem
ofsupplementing invitro experimental test procedures
with systems allowing (at least some type of) metabolic
activation (organ cultures); assessing the possible
embryotoxicpotential ofthe virostatic agent: acyclovir,
using a combined in vivo/in vitro approach ("whole-em-
bryo" culture technique).
Modification and Standardization of
the Whole-Embryo Culture
Technique
Overthelast5years wehavesystematicallymodified
andstandardizedthetechniqueofcultivatingearlypost-
implantationratormouseembryosasdescribedbyNew
and co-workers (5) so that it is now easier to use on a
larger scale for toxicological studies. The main advan-
tage of our method is the use of bovine serum as a
culture medium instead of rat serum (6). This modifi-
cation allows the study of a large number of samples
underdifferent experimental conditions usingthe same
batch of serum. The conditions for whole-embryo cul-
ture have been modified in such a way (adjustment of
gassing conditions, etc.) that the differentiationNEUBERT ET AL.
Table 1. Comparison ofrat and bovine serum as culture medium and different gassing procedures.
Prot, ,ug/
Medium YS, mW CR, mm' Som embryo Score ABN, %
Gassing I
0 hr 5% 02 5% C02
20 hr 20% 02 5% C02
32 hr 40% 02 5% C02
100% Rat serum, n = 15 3.78- 27.0 313.5 40.0 0
4.26b 3.48 26.0 223.0 40.0
4.02b 3.12 26.0 206.5 39.0
3.84b
86% Bovine serum + 14% Ty- 4.08 3.34 25.0 241.5 37.0 25
rode, 3.96 3.03* 24.0* 180.0* 35.5*
n = 20 3.75 2.79 23.0 130.5 27.0
Gassing II
0 hr 10% 02 5% C02
36 hr 50% 02 5% C02
100% Rat serum, n = 20 4.68 3.48 28.0 304.0 40.0 5
4.20 3.36 27.0 230.0 39.0
3.90 3.18 27.0 197.5 38.0
86% Bovine serum + 14% Ty- 4.98 3.54 27.0 250.0 39.0 0
rode, 4.50* 3.36 26.0 230.0 38.0*
n = 41 4.38 3.15 25.0 176.0 37.0
ayS = yolk sac diameter; CR = crown-rump length; Som = number of somite pairs; Prot = protein content.
bMiddle rows are median values; the numbers inthe bottom row represent the first quartile, the numbers in the top row represent the third
quartile.
*p = 0.01-0.05 (Mann-Whitney test).
achieved with bovine serum as culture medium is com-
parable to that obtained with rat serum (Table 1).
Wehavealsodevelopedandextensivelyused asimple
scoring system for documentation ofthe data in a com-
puterized form and for semi-quantifying nornal or ab-
normal development in culture (6).
The outcome ofthe development invitro and the con-
ditions for analyzing the effect ofchemicals in this sys-
tem may be further improved and standardized by in-
cubatingtheembryosat atemperature of38.8°Cinstead
of370C (Table 2); by adding 1 mL ofbuffer to 6 mL of
serum (thus facilitating the addition ofchemicals to the
medium); andsupplementingthebovine serumwith me-
thionine and purified hemoglobin (final concentrations:
7.5 mg/100 mL and 2.5 mg/mL, respectively). The ad-
dition of hemoglobin to the medium greatly improves
the fornation ofhemoglobin within the developing em-
bryos in culture.
Although a comparison ofthe development achieved
in culture with that occurring in the intact organism is
difficult because ofthe considerable variability in vivo,
it seems fair to state that the technique now used
embryonic development achieved in culture-essen-
tiallyresembles that seenin vivo withrespectto crown-
rump length, number of somite pairs, and score; the
median protein content is about 85% of that of corre-
sponding embryos developed in the living organism.
Abnormal Development Induced by
Valproic Acid in Whole-Embryo
Culture
From a large series of experiments performed with
valproic acid (VPA) we shall present here only a few
data to illustrate the versatile applicability of the
Table 2. Comparison ofdevelopment of rats in whole-embryo culture at 37.0 ± 0.20C and 38.8 ± 0.20C incubation temperature
(bovine serum).
Incubation temperature YS, mm' CR, mma Som0 Prot, ,ug/embryo Score ABN, %
4.20b 3.21 24.0 172.3 35.0
37.0 ± 0.20C 3.96b 2.94t 24.0* 141.0 33.Ot 10
n = 20 3.78b 2.65 23.0 111.5 28.0
4.26 3.44 26.0 218.8 37.0
38.8 ±0.2C 4.08 3.30 25.0 185.5 35.0 0
n = 12 3.90 2.91 24.0 151.0 34.0
YS = yolk sac diameter; CR = crown-rump length; Som = number of somite pairs; Prot = protein content.
bMiddle row are median values; the numbers in the bottom row represent the first quartile, the numbers in the top row represent the third
quartile.
*p= 0.01-0.5 (Mann-Whitney test).
tp v 0.01 (Mann-Whitney test).
90IN VIVO AND IN VITRO STUDIES ON PRENATAL TOXICITY
method. Abnormal development in whole-embryo cul-
ture induced byvalproic acid wasfirst described byKao
et al. (7) and has been extensively studied by Brown
(8). Since the teratogenic action of VPA has predomi-
nantly been demonstrated in vivo with mice, it is in-
teresting to note that typical defects seen in mice (pre-
dominantly defects in the head region) can also be
observed in vitro with rat embryos-a species which
has not been found so far to respond readily to VPA
with the formation of CNS abnormalities in vivo. The
susceptibility ofthe rat embryo to VPA in vitro can be
shown on the macroscopic (Fig. 1) as well as the mi-
croscopic level (Fig. 2), especially at the head region
and the somites.
We have shown (9) that one ofthe VPA metabolites
(4-en-VPA) is similarly active in inducing abnormal de-
velopment in vitro as VPA itself (Fig. 3 and Table 3),
whereas another chemically similar derivative (2-en-
VPA) is completely inactive in this respect. 4-en-VPA
induces an additional type of gross structural abnor-
mality in vitro, i.e., cardiac defects (Table 4). This ex-
ample clearly shows that in vitro techniques are espe-
cially suited to assess toxic effects ofmetabolites in the
absence of the original compound and under defined
experimental conditions.
Since embryos are routinely standardized with re-
\*!^¢[<*3b~~,. ,4w%z,Fr, *1~~~~~~~~~~~~~~4
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FIGURE 2. Effect of valproic acid (VPA) on rat embryos in whole-
embryo culture (48 hr incubation): lateral saggital section of an
embryo; the alteration of the somite structures is obvious:
(A) control medium; (B) + 0.6 mM VPA; t = somites.
FIGURE 1. Effect of valproic acid (VPA) on rat embryos in whole-
embryo culture (48-hrincubation): (A) control medium (6 mL bo-
vine serum + 1 mL Tyrode's buffer); (B) + 0.6 mM VPA; (C) +
1.2 mM VPA; (D) + 1.8 mM VPA. A = head; T = somites; O
= pericardial dilatation; * = incurvation ofthe spine.
FIGURE 3. Effect of4-en-VPA on the development ofrat embryos
in whole-embryo culture (48 hr incubation): (A) control medium;
(B) + 1.8 mM 4-en-VPA; A = head; T = somites; * = heart
tube.
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Table 3. Influence of 4-en-VPA (0.6 mM, 1.2 mM, and 1.8 mM) on the development of rat embryos in "whole-embryo" culture.
Abnorn. per
4-en-VPA, mm YS, mm CR, mm Som Prot, Fg/emb. Score Abnormalities, % embryo
4.77b 3.61 26.2 249 37
Control 4.47b 3.36 25.0 203 36 0 0
n = 18 4.29 3.11 24.7 146 35.7
4.75 3.37 26.0 175 36.2
0.6 mM 4.50 3.15* 25.0 150t 34.5 0 0
n = 18 3.97b 2.97 22.7 105 33
4.20 3.18 24.0 162 35
1.2 mM 4.02* 2.58t 23.5t 94t 32t 40 3 x 1 Abn.
n = 15 3.66 2.16 20.0 65 20 3 x 2Abn.
4.05 2.11 14.0 78 20 2 x 1 Abn.
1.8 mM 3.90t 1.89t 14.Ot 69t 16t 100 4 x 2 Abn.
n =14 3.84 1.50 12.0 51 15 8 x 3Abn.
aYS = yolk sac diameter; CR = crown-rump length; Som = number of somite pairs; Prot = protein content.
bMiddle row are median values; the numbers in the bottom row represent the first quartile, the numbers in the top row represent the third
quartile.
*Significant difference (p = 0.01).
tSignificant difference (p S 0.01) to the control group.
Table 4. Type of abnormalities observed after treatment with
VPA and 4-en-VPA in the whole embryo culture.
Concen- Abnormality, %
tration, Neural
mM n tube Shape Heart
Valproic acid 1.8 15 60 100 0
4-en-Valproic 1.8 14 85 92 64
acid
spect to the developmental stage for in vitro studies
when initiating the incubation, the variability of the
development in culture is much smaller than the con-
siderable variability of embryonic development within
the living organism. This fact holds true for many cul-
ture methods.
Table 5 gives an example ofthe variability observed
in mouse embryos in vivo. Such studies have been per-
formed with various strains of rats and mice (10) and
have given very similar results: there was always a
considerable inter-andintralittervariationinthestages
ofnormal prenatal development. This may be an expla-
nation for the variability of outcome regularly seen
when assessing embryotoxic effects in vivo. The ex-
ample given in Table 5 concerns an inbred strain in
which one would expect the highest degree ofsynchro-
nization. The variability seen-as indicated by-the so-
mite stages-is considerable. For the 62 embryos eval-
uated, a median value of40 somite pairs was found for
11-day-old embryos with a maximum of 44 and a mini-
mum of29 somites.
In contrast to this, the high degree ofreproducibility
of an in vitro system is shown, for example, for the
morphogeneticdifferentiation ofmouse limbbudsincul-
ture (Fig. 4). Because the explants can be standardized
at the initiation ofthe culture (according to the somite
stage of the embryos: + 1 somite stage) all the limbs
can be made to develop in a synchronized manner.
The in vitro techniques allow the exposure of the
FIGURE 4. Example of the uniform development of explants in an
organ culture system. Limb buds from 12-day-old mouse embryos
cultured for 6 days (11).
explants to the toxic agent for a limited period only;
before and after this period the cultivation is allowed
toproceed innormalculturemedium(12). We haveused
thewhole-embryo culturetechniquetorevealtheperiod
ofthe highest susceptibility ofthe rat embryo to VPA.
The results of our studies indicate that 9.5-day-old rat
embryos are most susceptible to VPA 12 to 18 hr after
the initiation of the culture (Table 6). This would cor-
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Table 5. Example ofthe intra- and inter-litter variability of a developmental stage (pairs of somites) in C57BI mice.'
No. of somite pairs
Litter no. 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 Litter size
1 1 1 1 3
2 1 1 1 3
3 1 1 1 1 4
4 1 1 1 2 5
5 1 1 3 1 6
6 1 2 2 1 6
7 1 1 2 2 1 7
8 1 2 3 6
9 3 2 1 6
10 1 2 1 2 1 7
11 3 3 1 2 9
Percentage 2 2 5 10 13 7 15 16 18 7 8% (n= 62)
distribution
aSomites were counted on day 11 ofgestation (between 1300 and 15°').
Table 6. Effect of a short-term exposure (6 hr) to valproic acid (1.8 mM) in the culture medium at different developmental phases on
growth and development of rat embryos in vitro.
Prot, ,ug/ Abnorn. per
Exposure YS, mma CR, mm2 Soma embryo' Scorea Abnormalities,a % embryo
4.68 3.42 27.3 220 37
Control 4.44 3.24 26.0 175 36 0 0
n = 35 4.14 3.12 24.0 134 35
4.50 3.18 26.0 159 36
0-6 hr 4.38 2.94 24.0 123 34 14 3 x 1 Abn.
n = 21 4.17 2.76 23.0 110 29
4.26 3.12 24.0 159 27 6 x 1 Abn.
12-18 hr 4.02t 2.82 23.0 140 25t 80 5 x 2 Abn.
n = 15 3.78 2.70 20.7 103 23 1 x 3 Abn.
aYS = yolk sac diameter; CR = crown-rump length; Som = number of somite pairs; Prot = protein content.
bMiddle row are median values; the numbers in the bottom row represent the first quartile, the numbers in the top row represent the third
quartile.
tSignificant difference (p G 0.01) between 0-6 hr and 12-18 hr.
respond to day 10.0 to 10.3 of gestation in the living
organism.
Studies on the Possible Potential of
Female Sex Hormones to Induce
Abnormal Cardiac Development in
Culture
There has been a considerable argument over the
question whether estrogens or gestagens have a tera-
togenic potential in man outside the genital tract and,
especially, whether they may induce cardiac abnormal-
ities (13-17). The data of one of the main studies pro-
viding some evidence in this direction (17) have been
doubted in their reliability (18) and apparently cannot
be used to provide evidence in this direction.
Sincetheproblemcannotbesolvedbyepidemiological
studies we attempted to obtain further clues on a pos-
sible teratogenic potential by testingthe effects ofsuch
female sex hormones on the heart development of rat
embryos inthewhole-embryo culture. With this system
the entire period of early heart development can be
monitored. Furthermore, extremely high concentra-
tions of these substances may be evaluated in vitro,
whereas in vivo the doses to be tested are very limited
due to the early occurrence of embryomortality in ro-
dents. The whole-embryo technique has been success-
fully used before to analyze the action of retinoic acid
on heart development in culture (19).
With the presently available techniques, it is difficult
to study development beyond day 12.5 of gestation in
the rat. Therefore, possible effects on later stages of
cardiac development (e.g., closure of the ventricular
septum) cannot completely be ruled out.
When testing a large number of estrogens and ges-
tagensusingwhole-embryo culture (Tables 7 and 8), we
did not find any indication ofthe ability ofthese agents
to interfere with cardiac development in rat embryos.
The studies were performed with 9.5- as well as with
10.5-day-old rat embryos cultured for 48 hr. All the
embryoshavebeenevaluatedhistologically, ineachcase
assessing serial sections. At extremely high concentra-
tions (> 1 ,ug/mL) most of these substances produced
necrosis intheembryo, predominantly attheCNSsites.
Even in these cases cardiac development was unim-
paired (Fig. 5). Taken together with all the epidemio-
logical evidence available to date (20,21), our data do
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Table 7. Evaluation of the effect offemale sex hormones on cardiac development in whole-embryo culture (48-hr incubation; culture
initiation: day 9.5).
YS, mm- CR, mma Soma Normal Retarded Abnornal
Controls 5.0 3.5 28.0 25 1 1
n = 27 4.5 3.3 27.0
4.2 3.0 26.0
,-Estradiol 4.7 3.3 26.5 8 1
(3 tg/mL)n 9 4.6 3.2 26.0
4.4 3.0 24.0
17-cx-Ethinylestradiol 7.8 3.6 26.0 10 3 2b
(10 ,zg/mL) n 15 4.5 3.2 25.0
4.4 3.0 24.0
DES 4.8 3.1 26.5 8 4 2b
(10 ig/mL) n 14 4.1 2.8 26.0
3.9 2.4 25.2
Progesterone 4.5 3.5 28.0 10 1
(1 ,tg/mL) n - 11 4.4 3.3 27.0
4.2 3.2 26.0
19-Norethisteron 5.1 3.9 30.0 8
(3 pig/mL) n = 8 4.5 3.2 27.0
4.3 3.0 27.0
aYS - yolk sac diameter; CR crown-rump length; Som = number of somites.
bNo cardiac abnormalities.
Table 8. Evaluation of the effect offemale sex hormones on cardiac development in whole-embryo culture (48-hr incubation; culture
initiation: day 10.5).
YS mma CR, mma soma Normal Retarded Abnormal
Controls 5.5 5.0 29.0 12
12 5.5 4.7 28.0
5.2 4.2 27.3
r-Estradiol 5.5 4.7 30.0 9
(3 .g/mnL) n - 12 5.4 4.5 29.0
5.0 4.2 28.5
17-a-ethinylestradiol 5.6 4.6 29.3 6
(10 ,ug/mL) n 6 5.3 4.2 27.5
4.4 3.9 24.0
IDES 5.5 4.4 28.0 6 -
(3 ptg/mL) n 6 5.2 4.3 27.5
5.0 4.1 26.8
Progesterone 5.5 5.0 28.5 8 1
(3 p.g/mL) n = 9 5.2 4.4 27.0
5.2 4.1 26.0
19-Norethisteron 5.5 4.6 28.3 8
(3 p.g/mL) n = 8 5.5 4.5 27.5
5.4 4.2 26.8
aYS = yolk sac diameter; CR crown-rump length; Som = number of somites.
bNo cardiac abnormalities.
not support the speculation that female sex hormones
interfere with cardiac development.
Studies on Assessing the
Teratogenic Potential of TBTO*
Bis(tri-n-butyltin) oxide (TBTO)is amolluscocide and
fungicide which is widely used. Its application may in-
*The term "teratogenic" is defined differently by different inves-
tigators in the field. Therefore, it is so ill defined that its significance
for atoxicological risk assessment is small. It may evenbemisleading
(e.g., for lawstiits). Ifpossible, it should be avoided and replaced by
crease in the future. It is, therefore, of importance to
learn whether this substance possesses a potential to
interfere with prenatal development. Again, it was at-
tempted to solve this problemusing a combined invivol
in vitro approach. In collaboration with WHO we have
performed in vivo experiments in mice. From these
studies (22) it can be concluded that TBTO seems to
exhibit embryotoxic and fetotoxic effects only at doses
stating which kind ofalteration is observed (specific congenital gross
structural abnormality, special dysfunction, etc.). Ifwe use the tern
at all it is for us synonymous with "inducing congenital gross struc-
tural abnormalities," not including certain "minor" abnormalities, an-
omalies, signs ofretardation, or dysjunctions.
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FIGURE 5. Rat embryo after 48-hr cultivation; treatment with 10 pig/ML 17-a-ethiny'lestradil; culture started on day 9.5 of gestaio;
(A) saggital section (t) necroses in somites; (B) magnification of the heart: unimpaired development showing (1) atrium commune;
(2) ventriculus communis; (3) tuncuis arteriosus.
which are close to those producing maternal toxicity
(Table 9).
The embryotoxicity and fetotoxicity ofTB3TO I's com-
pared with maternal toxicity (mortality) in Table 10.
From these data it is obvious that embryotoxicity with
this substance occurs close to maternal toxi-city. The
procedure of calculating ratios of relative embryotox-
icity-as we have suggested (23)..-requires the estab-
Table 9. Embryo/fetotoxicity of TBTO in mice.
Controls
TBTO dose
5 pL/k 10 j±L/1g 30 p.L/kg
Live fetuses 1154 248 204 21
%Resorptions 9.1 9.8 9.7 58.8
Average 1.13 ± 0.12 1.19 ±t 0.08 1.10 ± 0.15 0.91 ± 0.19
weight of
fetuses, g
Cleft palates, 8 (0.7%) 4 (2%) 14 (7%) 10 (48%0,)
Minor skeletal 85 (7%) 28 (11%) 22 (10%) 8 (38%)
deformities
Table 10. Relative embryotoxic risk factors for TBTO.
Risk factor
Fetal LD6(/niaternal LD,o 30/74 --0.41
Fetal LDw/maternal LD= > 20/45 > 0,44
EDw, cleft paJatie/mat.ernaal LDwo 80/45 = 0AJ7
ED. dleft palate/maternal Woo > 10/45 > 0.22
isQhment ofdose-response relationships. Furthermore,
maternaltoxicity-mustbeevaluatedinpregnantanimals
ofthe same strain. It iscompletely worthlezsswith isuch
an approach torely on data obtained fromnonpregnant
animals or from the literature as has beensuggested by
some investigators, since the variability of estimat'ing
the LDw value with d-ifferent strains and in different
laboratories is well known, and data may vary by one
order ofmagnitude.
Subsequent studies using the limb bud organ culture
system revealed an exceptional capabilitY of thi's sub..
stance to interfere with morphogenet'ic djifferentiation
in vitro (Table 11):- concentrations as low as 130 nM (30
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Table 11. Effect of TBTO on limb bud differentiation in vitro.
TBTO Interference with developmenta
concentration, nM day 11 day 12
17 0 0
50 + 0
170 ++ +
500 +++ ++
1700
ao = no effect; + = clear-cut effect; + + = strong effect; + + +
= clearly abnormnal differentiation; - = completely inhibited growth
and differentiation.
FIGURE 7. Effect of cyclophosphamide on limb bud differentiation
inculture subsequent to induction ofmonooxygenase activitywith
PCBs (3 x 200mg/kgAroclorA60) inutero. Hindlimbs of12-day-
oldmouseembryos: (a) controls; (b) + cyclophosphamideinvitro.
from embryos 0 R G A N Evaluation
of pretreated C U LTURE of Explants
/the presence,\
/ of potential \
teratogens
which require metabolization
to the active form
e.g. cyclophosphamide
nitrosamines
thalidomide derivatives
etc.
FIGURE 6. Experimental design for studying substances which re-
quire metabolic activation within the explants to interfere with
morphogenetic differentiation.
ng/mL) strongly inhibited the development in culture
(24). This is one of the lowest concentrations of a sub-
stance ever found to interfere with development in this
organ culture system.
Whenmeasuringthetincontentwithintheembryonic
tissues of mice injected with TBTO, we found concen-
trations (22) which, ifcaused by original TBTO, should
be more than sufficient to induce embryotoxicity. We
are presently involved in an attempt to analyze the
cause of this apparent discrepancy. One explanation
FIGURE 8. Effect ofdimethylnitrosamine (DMNA) on limb bud dif-
ferentiation in culture subsequent to induction ofmonooxygenase
activity with 3-naphthoflavone (3 x 150 mg/kg) in utero. Fore-
limbs of11-day-old mouse embryos: (a) controls; (b) + DMNAin
vitro.
could be that a metabolite of TBTO with a lower em-
bryotoxic potential accumulates within the embryo. To
demonstrate this, the experiments have to be supple-
mented with further pharmacokinetic studies and an
assessment ofthe (presumably lower) potential ofsuch
96IN VIVO AND IN VITRO STUDIES ON PRENATAL TOXICITY
FIGURE 9. Mouse limb buds on day 11 ofgestation after 4 days of culture. (Left) limb buds in assays containing a reconstituted cytochrome
P-450 system, NADPH, and 100 ,ug/mL cyclophosphamide; (right) control assays containing the same components minus NADPH or
cyclophosphamide; (top row) cytochrome P-450 concentration: 90 pmole/mL; (bottom row) cytochrome P-450 concentration: 9 pmole/mL.
Table 12. Species differences in the development of monooxygenases.a
Ratb Marmosetb
Cou. 450 Res., 40 Mo. 3000 Cou. 263 Res. 179 Mo. 2000
Developmental c
stage
- 2 days 2 80-90
1 day 8
Birth + 20 46
1 day
2 days 78 100
3 days 20
1 week 64 100 95
2 weeks 100
1 month 6 100
2 months 100
aCou. = ethoxycoumarin O-deethylase; Res. = ethoxyresorufin O-deethylase; Mo. = ethylmorphine N-demethylase.
bThe data are given in (%) of adult enzyme activity. 100% = pmole/mg protein-min.
cAlready 20% on day 60 ofgestation.
- = not detectable.
aTBTO metabolite to interfere with morphogenetic dif-
ferentiation in vitro.
Problems Involved in
Supplementing in Vitro Systems
with Xenobiotic-Activating
Capacities
One of the disadvantages of many in vitro systems
utilizing embryonic rodent tissues is the inability of
these explants to respond to metabolic activation. Es-
pecially with organ culture systems, the simple addition
of microsomal fractions (or S-9-mix) is completely un-
satisfactory, since these crude fractions strongly inter-
fere with development inculture. Anotherapproachhas
been to perform organ cultures in the presence of
"feeder cells" capable ofat least some functions ofdrug
metabolism. While this latter approach has been suc-
cessfully used in a few laboratories (25), it also has a
number oflimitations, especially since the spectrum of
the type ofmetabolic activation attainable with the sup-
plementing cells (including hepatocytes) is at present
quite limited.
For anumberofyears we have been tryingtwo other
approaches: to induce the capacity for metabolic acti-
vation within the explants to be used for the organ
culture studies, and to isolate defined cytochrome P-450
fractions and to add a reconstituted system to the cul-
ture medium. The first approach-if feasible-would
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Table 13. Effect ofacyclovir and physiological deoxynucleosides (2'-deoxyguanosine, 2'-deoxyadenosine) on growth and development
of9.5 day-old rat embryos in culture (En = 213).
YS, mma CR, mma Soma Prot, tLgfembryo' Score ABN, %
Control 4.56 3.60 27.0 283.5 38.0 0
n = 44 4.32 (100%) 3.36 (100%) 26.0 (100%) 234.5 (100%) 37.0
4.20 3.18 25.0 176.0 35.25
25 p.M Acyclovir 4.50 3.30 26.0 196.0 36.0 0
n = 27 4.26 (99%) 3.06 (91%)* 25.0* 150.0 (64%)* 36.0*
4.08 2.88 23.0 123.5 24.0
50 ,uM Acyclovir 4.51 3.36 27.0 175.0 38.0 28%
n = 18 4.35 (101%) 3.15 (94%)* 26.0 130.0 (55%)* 34.5*
4.17 2.88 24.0 110.0 32.75
100 p.M Acyclovir 4.80 3.36 27.0 174.5 33.0 95%
n = 19 4.56 (106%)* 3.00 (89%)* 26.0 137.5 (59%)* 32.0*
4.38 2.82 25.0 122.3 31.0
200 p.M 2'-Desoxyguanosine 4.65 3.76 27.75 284.0 38.0 0
n = 16 4.53 (105%) 3.45 (103%) 26.5 252.0 (108%) 37.0
4.33 3.25 26.0 225.0 36.0
aYS = yolk sac diameter; CR crown-rump length; Som = number ofsomite pairs; Prot = protein content; ABN = abnornalities.
bMiddle rows are median values; thenumbers in the bottom row represent the firstquartile; the numbers in the top row represent the third
quartile.
*Significantly different from control group at p < 0.05 (Mann-Whitney test).
Table 14. Influence on acyclovir on the ear development of 9.5-day-old rat embryos in vitro.
Acyclovir concentration
Ear development Control, n = 44 10piM, n = 19 25 ,uM, n = 27 50 pM, n = 18 100 pM, n = 19 200 puM, n = 21
Rec. dors. present, 71% 58% 26% 28% 10.5%
otic vesicle closed
Otic vesicle closed 18% 42% 30% 5.5% 10.5%
Otic vesicle slightly 11% - 30% 33% 37% 9.5%
open
Otic vesicle half - 3% 5.5% 10.5% 19%
open
Otic pit - 11% 28% 31.5% 71.5%
Table 15. Overview ofthe histological results in the different test groups.
Control;
10 puM Acyclovir;
200 and 500 p.M
Tissue 2'-desoxyguanosine 25 ,uM Acyclovir 50 ,uM Acyclovir 100 ,uM Acyclovir 200 ,uM Acyclovir
Neuroepithelium Multilayered Multilayered Multilayered; Monolayered; Monolayered;
partly monolayered Mitosis l Mitosis e l
Necroses I Necroses t 1
Central channel 0 0 Slightly dilated Dilated; Dilated I,
Necroses 1 Necroses I l
Telencephalon 0 0 Some poorly Poorly developed I Poorly developed I
developed or or completely or completely
completely missing missing missing
Ear Otic vesicle closed Otic vesicle not Otic pit partly Otic pit Ear plate, little
Cells cylindrical completely closed Necroses; Necroses I cell material;
Cells cylindrical Cells cylindrical Cells partly cubical Necroses I I;
Cells cubical
Somites Regular Regular Partly irregular; Irregular; Irreglar t;
"Frayed"; "Frayed"; "Frayed" I;
Necroses Necroses I I Necroses I I
be superior to all the other approaches, since the po-
tentially toxic substances would be metabolically acti-
vated by the target cells themselves. This is especially
important if short-lived active metabolites are to be
expected.
So far, only attempts that induce a special subtype
of monooxygenase activity: AHH = aryl hydrocarbon
hydroxylase, a cytochrome P-448-dependent enzyme
system, have been convincing. We have been able to
induce an AHH type of activity (e.g., benzo[alpyrene
98IN VIVO AND IN VITRO STUDIES ON PRENATAL TOXICITY
FIGURE 10. Effect of acyclovir in whole-embryo culture: (a) 9.5-
day-old rat embryo ( l ) in its membranes at the beginning ofthe
culture; (b)- (f) ratembryos after48hrofculture inbovine serum
with testsubstances addedtothemedium. Cultureinthepresence
of: (b) 200 ,uM 2'-deoxyguanosine (development corresponding to
controls); (c) 25 ,uM, (d) 50 ,uM, (e) 100 ,uM, and (f) 200 FM acy-
clovir, respectively, increasing extent of interference with pre-
natal development.
hydroxylase) at the stage of organogenesis in various
rodent embryos (26). Ithas beenfound to be much more
difficult to induce typical cytochrome P-450 activities in
embryonic tissues of rodents. Although some such en-
zyme activities may be detectable with the highly sen-
sitive methods available today (27), all the activities
studied up till now remained so low-even after at-
tempts to enhance the activities by various inducers-
that a reproducible and exploitable monooxygenase ac-
tivity sufficient for routine test purposes in vivo could
not be obtained.
Byusing very high substrate concentrations invitro,
it is feasible to test the potential to induce abnormal
development with explants or cells subsequent to an
enzyme induction in vivo. With this experimental set-
upapparently only some subtypes ofcytochrome P450-
dependent activities can be induced within the embry-
onic tissues of rats or mice. We have been successful
FIGURE 11. Effect ofacyclovir on the development ofthe ear in rat
embryos after 48-hr cultivation (whole-embryo culture) starting
with day 9.5 ofgestation: (a) untreated control: showing a closed
otic vesicle (4 ); (b) 100 ,uM acyclovir: otic vesicle (4 ) not yet
completelyclosed; (c) 200,.Macyclovir: oticplacodewithincipient
invagination (4 ), greatly reduced cell number.
with this experimental design (see schematic presen-
tation in Fig. 6) in studying abnormal development in
organ cultures with cyclophosphamide and dimethylni-
trosamine using explants ofembryos after induction of
monooxygenase activities with PCBs (Aroclor A60) or
,-naphthoflavone (28,29) in utero. Typical examples of
such an approach are shown in Figures 7 and 8.
With respect to the second approach, after many
years of attempts and failure we have now succeeded
in obtaining enzyme fractions of very high specific ac-
tivities which are tolerated by the explants in culture
(30). Using cyclophosphamide as a model substrate, a
pronounced and clear-cut metabolic activation is
achieved with the addition of 10 nM cytochrome P-450
fractions from various sources and the necessary com-
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FIGURE 12. Effect of acyclovir on development ofneuroepithelium
in rat embryos after 48-hr cultivation (whole-embryo culture)
startingwith day9.5ofgestation: (a) untreated control: neuroepi-
thelium in theregion ofthetelencephalic vesicle (N), mesenchyme
(M), ectodermal epithelium (*); (b) 200 t1M acyclovir: numerous
necroses in the neuroepithelium (N), mesenchyme (M) decreased
in amount, thin ectodermal epithelium (*).
plementing components (Fig. 9). The system developed
has itself a low toxicity since all the components have
been extensively purified and it can now be used for
many kinds of in vitro systems.
As a word ofcaution we would like to stress that by
adding drug-metabolizing capacity to a culture medium
it is possible to produce artifacts on the target cells (4),
i.e., results with products ofmetabolic activation which
have no relevance to the situation in vivo. Therefore,
a single result obtained with such a system has little
value with respect to toxicological risk assessment un-
less it is backed with additional results. This is a limi-
tation with almost all in vitro systems. Many results
reported intheliterature obtainedwithsubstances such
as thalidomide in vitro are not to be interpreted forthis
reason. In such situations, we have suggested (31) ana-
lyzing groups of chemically very similar derivatives
from which it is known that they exert different bio-
logical effects in vivo in order to verify whether the
result obtained is biologically meaningful.
It should be remembered that considerable species
differences exist with respect to the prenatal and peri-
natal development of the activity of drug-metabolizing
monooxygenases. These have to be considered if an ex-
trapolation of data from one species to another is at-
tempted. While the activity of cytochrome P-450-de-
pendent monooxygenases is extremely low or absent in
rodent embryos and early fetuses, such activity maybe
detectable in the livers ofprimates at rather early fetal
stages (32).
Table 12 gives some examples of differences in peri-
natal development ofsome monooxygenases in rats and
marmosets. Because of practical reasons we find the
marmoset to be a primate species which is especially
suited forspecial studiesinprenataltoxicity, andthere-
fore some data are included here. While typical cyto-
chrome P-450-dependent monooxygenases (e.g., ethyl-
morphine demethylation) are already detectable at day
60 ofgestation (duration ofpregnancy 140 days) in the
marmoset (Callithrixjacchus), the activity ofother en-
zymes (predominantly such of the cytochrome P-448
type) may develop even later than in the rat.
Withthe technique ofaddingreconstituted monooxy-
genases to invitro systems, we intend to study system-
atically the effect of monooxygenases of different spe-
cies-including those of primates-after induction by
different agents in various culture systems.
Assessment of Possible
Teratogenic Potential of Acyclovir
Using an in Vitrolin Vivo Approach
One of the best examples for the use of a combined
invitro/invivoapproachcomesfromrecentstudies per-
formed inourlaboratorytoelucidate apossible embryo-
toxic potential ofthe virostatic agent acyclovirwhich is
used for the treatment of herpes infections. Segment-
II tests performed before on a routine basis (treatment
on days 6-15 of pregnancy) have not shown any indi-
cation for an embryotoxic potential of this agent (33).
Sincethe doses that could be tested inthe experimental
animals in vivo are limited (because of an interfering
nephrotoxicity in these species), we initiated in vitro
studies using the whole-embryo culture technique.
The substance was clearly able to interfere with em-
bryonic development in vitro (Table 13 and Fig. 10) at
concentrations exceeding 25 pM (34). Serum concen-
trations measured in man under extreme therapeutic
conditions (IV application) approach 100 ,uM; serum
peakconcentrationstobeexpectedafteroralmedication
with the dose regime used today are in the range of 2
,M.
Abnormal development as shown in vitro-besides a
general retardation, especially at higher doses-pre-
dominantly concerns the shape of the head; most sus-
ceptible to the action ofacyclovir is the development of
the ear (Tables 14 and 15 and Fig. 11). Histologically,
necrosis can be seen in several parts of the embryos,
e.g., neuroepithelium, somites, ear, etc. (Table 15 and
Fig. 12).
The question arose why the substance had not been
found to induce abnormal development in vivo. Two
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FIGURE 13. Effect ofacyclovir on 11.5-day-old rat embryos in vivo and in vitro after 48-hr culture: (A) in vivo control; (B) 3 x 100 mg/kg
acyclovir (treatment on day 10 ofgestation); (C) 8 x 100 mg/kg acyclovir (treatment on days 9, 10, and 11 ofgestation); (a) in vitro control;
(b) + 100 ,M acyclovir; (c) + 100 pM acyclovir.
Table 16. Gross structural abnormalities produced by acyclovir in rats in vivo.'
Acyclovir treatment Evaluation on day 11.5
Day ofpregnancy Dose, mg/kg Somb Protb Score ABN, %
Control n = 22 26.5 353 40 0
26 299 40
25 244 40
9, 10, 11 n = 23 8 x 50 27 - 40 3 % head
26 40
25 40
10 n = 13 1 x 200 25 158 35 100 % head
24 135 33
24 114 33
aThe effect was evaluated on day 11.5 ofpregnancy; acyclovir was given SC.
BSOM = number ofsomites; Prot = ,ug/protein/embryo; ABN = abnormal embryos.
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explanations appeared possible: (a) the substance does
not reach the embryo in vivo at high enough concen-
trations to exert an embryotoxic potency, or, more
likely, (b) the dose regime routinely applied was not
adequate to allow the demonstration ofan effect. Since
the period of highest susceptibility could be deduced
from our in vitro studies (day 10 of gestation), we ap-
plied the substance at a high dose during one day of
pregnancy at the presumed susceptible period (Table
16). Surprisingly, the same type of structural abnor-
mality was found under these special conditions in vivo
when evaluated on day 11.5 of pregnancy as was seen
in vitro. Figure 13 shows a typical picture of the em-
bryos after treatment in vitro and in vivo.
To ourknowledge this is the first example ofan effect
which, afterbeingobserved invitro, hasbeenpredicted
to also have a potential of occurring in vivo and sub-
sequently has been demonstrated to be inducible in
vivo. We feel that this gives a good example of the
benefits of combining in vitro and in vivo tests for the
assessment of a possible embryotoxic potential of a
chemical.
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